Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 443

1.

Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.

Royston P, Barthel FM, Parmar MK, Choodari-Oskooei B, Isham V.

Trials. 2011 Mar 18;12:81. doi: 10.1186/1745-6215-12-81.

2.

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.

Bratton DJ, Phillips PP, Parmar MK.

BMC Med Res Methodol. 2013 Nov 14;13:139. doi: 10.1186/1471-2288-13-139.

3.

Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.

Choodari-Oskooei B, Parmar MK, Royston P, Bowden J.

Trials. 2013 Jan 23;14:23. doi: 10.1186/1745-6215-14-23.

4.

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.

Sydes MR, Parmar MK, Mason MD, Clarke NW, Amos C, Anderson J, de Bono J, Dearnaley DP, Dwyer J, Green C, Jovic G, Ritchie AW, Russell JM, Sanders K, Thalmann G, James ND.

Trials. 2012 Sep 15;13:168. doi: 10.1186/1745-6215-13-168.

5.

Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.

Royston P, Parmar MK, Qian W.

Stat Med. 2003 Jul 30;22(14):2239-56.

PMID:
12854091
6.

Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.

Bratton DJ, Parmar MK, Phillips PP, Choodari-Oskooei B.

Trials. 2016 Jul 2;17(1):309. doi: 10.1186/s13063-016-1382-5.

7.

Information time scales for interim analyses of randomized clinical trials.

Freidlin B, Othus M, Korn EL.

Clin Trials. 2016 Aug;13(4):391-9. doi: 10.1177/1740774516644752. Epub 2016 May 2.

PMID:
27136947
8.

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD, Morgan RC, Sanders K, Royston P.

Trials. 2009 Jun 11;10:39. doi: 10.1186/1745-6215-10-39.

9.

A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.

Sill MW, Rubinstein L, Litwin S, Yothers G.

Clin Trials. 2012 Aug;9(4):385-95. doi: 10.1177/1740774512450101. Epub 2012 Jul 18.

10.

Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.

Schmidt R, Burkhardt B, Faldum A.

Methods Inf Med. 2015;54(5):434-46. doi: 10.3414/ME14-02-0023. Epub 2015 Oct 2.

PMID:
26429500
11.

Applying a phase II futility study design to therapeutic stroke trials.

Palesch YY, Tilley BC, Sackett DL, Johnston KC, Woolson R.

Stroke. 2005 Nov;36(11):2410-4. Epub 2005 Oct 13.

12.

Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial.

Lesaffre E, Edelman MJ, Hanna NH, Park K, Thatcher N, Willemsen S, Gaschler-Markefski B, Kaiser R, Manegold C.

Ann Oncol. 2017 Jul 1;28(7):1419-1426. doi: 10.1093/annonc/mdx042.

PMID:
28184431
13.

Interim futility analysis with intermediate endpoints.

Goldman B, LeBlanc M, Crowley J.

Clin Trials. 2008;5(1):14-22. doi: 10.1177/1740774507086648.

PMID:
18283075
14.

Group-sequential methods for adaptive seamless phase II/III clinical trials.

Stallard N.

J Biopharm Stat. 2011 Jul;21(4):787-801. doi: 10.1080/10543406.2011.551335. Review.

PMID:
21516569
15.

Mixed response and time-to-event endpoints for multistage single-arm phase II design.

Lai X, Zee BC.

Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.

16.

Monitoring event times in early phase clinical trials: some practical issues.

Thall PF, Wooten LH, Tannir NM.

Clin Trials. 2005;2(6):467-78.

PMID:
16422307
17.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
18.

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdés-Márquez E, Stallard N, Friede T.

Mult Scler. 2011 Jan;17(1):81-8. doi: 10.1177/1352458510382129. Epub 2010 Aug 26.

PMID:
20798135
19.

Speeding up the evaluation of new agents in cancer.

Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P.

J Natl Cancer Inst. 2008 Sep 3;100(17):1204-14. doi: 10.1093/jnci/djn267. Epub 2008 Aug 26.

20.

On sample size determination in multi-armed confirmatory adaptive designs.

Wassmer G.

J Biopharm Stat. 2011 Jul;21(4):802-17. doi: 10.1080/10543406.2011.551336.

PMID:
21516570

Supplemental Content

Support Center